Nanobiotix S.A.
NBTX · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.01 | -0.05 | 0.09 |
| FCF Yield | -9.23% | -10.74% | -2.69% | 1.92% |
| EV / EBITDA | 194.99 | -3.77 | -9.37 | 159.61 |
| Quality | ||||
| ROIC | -6.15% | -333.42% | -67.26% | -2.87% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 3.23 | 0.30 | 0.27 | -0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 707.66% | 492.94% | 214.09% | 121.60% |
| Free Cash Flow Growth | -24.78% | -122.51% | -231.94% | 126.78% |
| Safety | ||||
| Net Debt / EBITDA | 20.55 | -0.03 | 0.74 | -17.49 |
| Interest Coverage | 0.22 | -5.53 | 0.00 | -0.41 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 6.21 | -36.76 | 30.24 | 25.96 |